

GENMAB A/S

ISIN: DK0010272202 WKN: - Asset Class: **Stock**

Company

2024/10/18 17:20:00



Price

1,563.50

DKK

Difference

-0.73%(-11.50)



Contact Details

GENMAB A/S

Tel: +45-70-20-27-28

--

Fax: +

Carl Jacobsens Vej 30, Valby
2500 Copenhagen

Web: <http://www.genmab.com>

E-mail: info@genmab.com

Company Profile

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	33,139,000,000		28,377,000,000		22,736,000,000	
Common stock capital		66,000,000		66,000,000		66,000,000
Fixed assets	2,150,000,000		1,901,000,000		1,891,000,000	
Equity capital of a company		31,610,000,000		27,441,000,000		22,196,000,000
Cash and cash equivalents	14,867,000,000		9,893,000,000		8,957,000,000	
Accrued liabilities		0		11,000,000		13,000,000
Other assets	-		-		-	
Current liabilities		2,484,000,000		1,823,000,000		1,568,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		1,195,000,000		1,014,000,000		863,000,000
Different income		-		-		-
Other liabilities		515,000,000		480,000,000		487,000,000
Total assets	35,289,000,000	35,289,000,000	30,278,000,000	30,278,000,000	24,627,000,000	24,627,000,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	2,204	1,660	1,212
Equity ratio	89.57%	90.63%	90.13%
Debt-equity ratio	11.64%	10.34%	10.95%

Others

	2023	2022	2021
Tax Expense Rate	22.80%	21.51%	24.48%

GENMAB A/S

ISIN: DK0010272202 WKN: - Asset Class: **Stock**

Income statement

	2023	2022	2021
Turnover	16,474,000,000	14,595,000,000	8,482,000,000
Net income	4,352,000,000	5,522,000,000	3,008,000,000
EBIT	633,150,000	902,088,000	509,066,000
Operating income before taxes	5,637,000,000	7,035,000,000	3,983,000,000
Cash Flow	7,380,000,000	3,912,000,000	2,228,000,000
Net interest income	912,000,000	303,000,000	184,000,000
Research and development expenses	7,435,000,000	5,346,000,000	4,004,000,000
Income taxes	1,285,000,000	1,513,000,000	975,000,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	1,001,595	1,178,151	937,779

Board of Directors

Deirdre Connelly	Chairman of Supervisory Board
Anders Gersel Pedersen	Member of Supervisory Board
Mijke Zachariasse	Member of Supervisory Board
Paolo Augusto Paoletti	Member of Supervisory Board
Elizabeth O'Farrell	Member of Supervisory Board
Martin Schultz	Member of Supervisory Board
Pernille Erenbjerg	Member of Supervisory Board
Rolf K. Hoffmann	Member of Supervisory Board
Takahiro Hamatani	Member of Supervisory Board

Members of Management Board

Jan G. J. van de Winkel	Chairman of Managing Board
Judith Klimovsky	Member of Executive Committee
Martine J. van Vugt	Member of Executive Committee
Anthony Mancini	Member of Executive Committee
Anthony Pagano	Member of Executive Committee
Birgitte Stephensen	Member of Executive Committee
Christopher Cozic	Member of Executive Committee
Tahamtan Ahmadi	Member of Executive Committee